High patient burden with moderate-to-severe atopic dermatitis

July 5, 2018

(HealthDay)—Patients with moderate/severe atopic dermatitis (AD) have higher patient-reported burden than those with mild AD, regardless of disease control, according to a study published online July 3 in JAMA Dermatology.

Eric L. Simpson, M.D., from the Oregon Health & Science University in Portland, and colleagues characterized the patient-reported burden of AD in a cross-sectional study using data from six academic medical centers. Using the Patient-Oriented Scoring Atopic Dermatitis, they stratified 1,519 adults with AD by AD severity as mild or moderate/severe. Those with moderate/severe using systemic immunomodulators/phototherapy were further stratified according to disease control.

The researchers found that the 830 patients with moderate/severe AD reported more severe itching and pain, greater adverse effects on sleep, higher prevalence of anxiety and depression (50.2 versus 27.3 percent), and greater health-related quality-of-life impairment compared to mild AD (689 patients). For with moderate/severe AD, higher burdens of itch and sleeping symptoms were reported for those with inadequate disease control despite treatment with systemic immunomodulators or phototherapy versus those with controlled disease; this included more days per week with itchy skin (5.7 versus 2.7) and higher proportions with itch duration greater than half a day (22.8 versus 2.9 percent).

"Regardless of , the burden of moderate/severe AD was higher than mild AD, suggesting a need for more effective therapies for moderate/severe disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Regeneron Pharmaceuticals and Sanofi, which funded the study.

Explore further: Physicians report high rate of uncontrolled atopic dermatitis

More information: Abstract/Full Text

Related Stories

Physicians report high rate of uncontrolled atopic dermatitis

December 1, 2017
(HealthDay)—Physicians rate a high proportion of patients with atopic dermatitis (AD) as having inadequate disease control, according to a study published online Nov. 13 in the Journal of Dermatology.

Moderate, severe OSA linked to elevated blood coagulability

August 21, 2017
(HealthDay)—Moderate and severe obstructive sleep apnea (OSA) are associated with elevated blood coagulability markers, according to a study published online Aug. 17 in JAMA Otolaryngology-Head & Neck Surgery.

Certolizumab looks promising for moderate-to-severe psoriasis

May 25, 2018
(HealthDay)—Twice-weekly certolizumab biologic appears to be both safe and effective for the treatment of moderate-to-severe chronic plaque psoriasis, according to a study published online April 13 in the Journal of the ...

Dupilumab effective in atopic dermatitis

October 4, 2016
(HealthDay)—Dupilumab is effective for patients with moderate-to-severe atopic dermatitis that is inadequately controlled by topical treatment, according to a study published online Oct. 1 in the New England Journal of ...

Methotrexate, azathioprine seem safe long-term for dermatitis

December 21, 2017
(HealthDay)—Methotrexate and azathioprine appear to be effective and safe as maintenance treatments in moderate-to-severe atopic dermatitis for up to five years, according to research published online Dec. 13 in the British ...

Sustained use of oxymetazoline cream efficacious for rosacea

May 18, 2018
(HealthDay)—Oxymetazoline is safe and effective for the treatment of moderate-to-severe persistent erythema of rosacea, according to a study published in the June issue of the Journal of the American Academy of Dermatology.

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.